Skip to main content

Table 1 Summary of patient demographics and baseline characteristics by body weight and BMI

From: Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

 

Body weight

BMI

Total population (N = 936)

Categories

Thresholds

Categories

Thresholds

≤60 kg (N = 144)

> 60–75 kg (N = 319)

> 75–90 kg (N = 288)

> 90 kg (N = 185)

< 100 kg (N = 819)

≥100 kg (N = 117)

≤25 kg/m2 (N = 323)

> 25–30 kg/m2 (N = 330)

> 30 kg/m2 (N = 283)

< 36 kg/m2 (N = 844)

≥36 kg/m2 (N = 92)

Female, n (%)

125 (87)

198 (62)

149 (52)

76 (41)

499 (61)

49 (42)

188 (58)

179 (54)

181 (64)

482 (57)

66 (72)

548 (59)

Mean (SD) age, years

46.5 (18.7)

51.5 (14.0)

52.1 (12.0)

50.1 (11.3)

50.9 (14.2)

48.9 (11.3)

47.8 (16.4)

53.1 (13.0)

51.0 (11.0)

50.9 (14.1)

48.5 (11.7)

50.6 (13.9)

Mean (SD) duration of asthma, years

17.4 (12.1)

20.3 (14.9)

20.0 (14.5)

20.0 (14.9)

19.8 (14.4)

18.9 (14.6)

17.9 (13.8)

20.1 (14.4)

21.4 (14.9)

19.4 (14.2)

23.1 (15.4)

19.7 (14.4)

Clinically significant exacerbations in the previous year, n (%)

 Mean (SD)

3.4 (2.2)

3.2 (2.7)

3.0 (1.8)

3.2 (2.2)

3.2 (2.3)

3.2 (2.2)

3.2 (2.4)

3.1 (2.2)

3.2 (2.1)

3.2 (2.3)

3.3 (2.4)

3.2 (2.3)

 2

72 (50)

187 (59)

171 (59)

91 (49)

464 (57)

57 (49)

181 (56)

188 (57)

152 (54)

472 (56)

49 (53)

521 (56)

 3

28 (19)

61 (19)

52 (18)

49 (26)

160 (20)

30 (26)

60 (19)

73 (22)

57 (20)

170 (20)

20 (22)

190 (20)

 ≥ 4

44 (31)

71 (22)

65 (23)

45 (24)

195 (24)

30 (26)

82 (25)

69 (21)

74 (26)

202 (24)

23 (25)

225 (24)

Receiving maintenance OCS therapy at baseline, n (%)

 Yes

24 (17)

80 (25)

71 (25)

52 (28)

196 (24)

31 (26)

79 (24)

74 (22)

74 (26)

204 (24)

23 (25)

227 (24)

 No

120 (83)

239 (75)

217 (75)

133 (72)

623 (76)

86 (74)

244 (76)

256 (78)

209 (74)

640 (76)

69 (75)

709 (76)

Mean (SD) % predicted pre-bronchodilator FEV1

62.8 (16.8)

59.4 (17.8)

59.1 (15.8)

57.7 (16.6)

59.5 (16.8)

59.4 (17.2)

61.4 (17.7)

58.7 (16.6)

58.3 (16.1)

59.7 (17.0)

58.1 (15.7)

59.5 (16.8)

Mean (SD) SGRQ total score

45.5 (20.6)

45.0 (18.6)

47.7 (19.1)

50.8 (17.5)

46.6 (19.2)

50.6 (17.1)

43.9 (19.5)

46.5 (18.5)

51.4 (18.1)

46.3 (19.0)

53.7 (17.4)

47.1 (18.9)

Mean (SD) ACQ-5 score

2.2 (1.3)

2.2 (1.1)

2.1 (1.2)

2.5 (1.2)

2.2 (1.2)

2.4 (1.1)

2.2 (1.1)

2.1 (1.2)

2.4 (1.2)

2.2 (1.2)

2.5 (1.2)

2.2 (1.2)

Geometric mean (SD of log) blood eosinophil count, cells/μL

370 (1.13)

320 (0.93)

300 (0.90)

360 (0.87)

320 (0.96)

360 (0.85)

350 (0.98)

310 (0.90)

310 (0.96)

320 (0.96)

330 (0.81)

330 (0.95)

  1. Percentages may not add up to 100, due to rounding
  2. Abbreviations: ACQ Asthma Control Questionnaire, BMI Body mass index, FEV1 Forced expiratory volume in 1 s, OCS Oral corticosteroid, SD Standard deviation, SGRQ St George’s Respiratory Questionnaire